About Us

ProtAffin AG was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. We are well financed by a syndicate of 5 international venture capital investors.

The company has a balanced “platform-product” strategy: a lead compound in pre-clinical development and a core discovery technology by which we are supporting a sustainable pipeline of products via our unique CellJammer^® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products.

We are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. We plan to collaborate with Pharma and Biotech companies interested to access our technology for the development of novel anti-inflammatory products with a unique mechanism of action.

 

  Company Profile - English


   Firmenprofil - Deutsch